These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma. Jamal-Hanjani M; Pettengell R Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1441-8. PubMed ID: 21905966 [TBL] [Abstract][Full Text] [Related]
4. Pixantrone for the treatment of aggressive non-Hodgkin lymphoma. Mukherji D; Pettengell R Expert Opin Pharmacother; 2010 Aug; 11(11):1915-23. PubMed ID: 20569087 [TBL] [Abstract][Full Text] [Related]
5. Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas. El-Helw LM; Hancock BW Expert Opin Investig Drugs; 2007 Oct; 16(10):1683-91. PubMed ID: 17922631 [TBL] [Abstract][Full Text] [Related]
6. Nuclear Trapping through Inhibition of Exosomal Export by Indomethacin Increases Cytostatic Efficacy of Doxorubicin and Pixantrone. Koch R; Aung T; Vogel D; Chapuy B; Wenzel D; Becker S; Sinzig U; Venkataramani V; von Mach T; Jacob R; Truemper L; Wulf GG Clin Cancer Res; 2016 Jan; 22(2):395-404. PubMed ID: 26369630 [TBL] [Abstract][Full Text] [Related]
7. The role of pixantrone in the treatment of non-Hodgkin's lymphoma. Borchmann P; Schnell R Expert Opin Investig Drugs; 2005 Aug; 14(8):1055-61. PubMed ID: 16050797 [TBL] [Abstract][Full Text] [Related]
8. Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. Keating GM Drugs; 2016 Oct; 76(16):1579-1586. PubMed ID: 27757832 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Sancho JM; Navarro B; Soler Campos JA; de Oteyza JP; de Barrenetxea Lekue C; Bregni M; Grasso Cicala S; Spione M; Mombiedro C; Soler B; Zinzani PL Eur J Haematol; 2020 May; 104(5):499-508. PubMed ID: 31997425 [TBL] [Abstract][Full Text] [Related]
10. Panobinostat for the management of multiple myeloma. Sivaraj D; Green MM; Gasparetto C Future Oncol; 2017 Mar; 13(6):477-488. PubMed ID: 27776419 [TBL] [Abstract][Full Text] [Related]
11. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Pettengell R; Coiffier B; Narayanan G; de Mendoza FH; Digumarti R; Gomez H; Zinzani PL; Schiller G; Rizzieri D; Boland G; Cernohous P; Wang L; Kuepfer C; Gorbatchevsky I; Singer JW Lancet Oncol; 2012 Jul; 13(7):696-706. PubMed ID: 22652183 [TBL] [Abstract][Full Text] [Related]
12. Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions. Beeharry N; Di Rora AG; Smith MR; Yen TJ Cancer Biol Ther; 2015; 16(9):1397-406. PubMed ID: 26177126 [TBL] [Abstract][Full Text] [Related]
13. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib. Malek E; Driscoll JJ Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530 [TBL] [Abstract][Full Text] [Related]
14. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643 [TBL] [Abstract][Full Text] [Related]
15. Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper. Zinzani PL; Corradini P; Martelli M; Minotti G; Oliva S; Spina M; Barosi G; Tura S Eur J Haematol; 2016 Dec; 97(6):554-561. PubMed ID: 27124765 [TBL] [Abstract][Full Text] [Related]
16. Pixantrone: novel mode of action and clinical readouts. Minotti G; Han H; Cattan V; Egorov A; Bertoni F Expert Rev Hematol; 2018 Jul; 11(7):587-596. PubMed ID: 29912583 [TBL] [Abstract][Full Text] [Related]
17. The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma. Muszbek N; Kadambi A; Lanitis T; Hatswell AJ; Patel D; Wang L; Singer JW; Pettengell R Clin Ther; 2016 Mar; 38(3):503-15. PubMed ID: 26856929 [TBL] [Abstract][Full Text] [Related]
18. Pixantrone as a novel MCM2 inhibitor for ovarian cancer treatment. Chen Q; Sun Y; Li H; Liu S; Zhang H; Cheng Z; Wang Y Eur J Pharmacol; 2024 Sep; 979():176835. PubMed ID: 39032764 [TBL] [Abstract][Full Text] [Related]
19. An evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma. Hübel K Expert Opin Pharmacother; 2018 Nov; 19(16):1829-1834. PubMed ID: 30269614 [TBL] [Abstract][Full Text] [Related]
20. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. Salvatorelli E; Menna P; Paz OG; Chello M; Covino E; Singer JW; Minotti G J Pharmacol Exp Ther; 2013 Feb; 344(2):467-78. PubMed ID: 23192654 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]